Effects of Continuous Airway Pressure on the ability to heat and humidify air in healthy subjects.

Effects of Continuous Airway Pressure on nasal mucosal temperature and airway geometry in healthy subjects. (TS-NACLa)

Status

Not yet recruiting

Phases

Unknown

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12605000797673

Acronym

TS-NACLa

Enrollment

Registered

2005-12-20

Start date

2006-02-01

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Participants will be randomised to receive a pressure of -5cm; 0cm; 5 or 10cmH20 for a period of 12minutes. Participants will return a further 3 times, at which time they will be randomised to receive one of the remaining pressures. Each pressure application will occur not less than two days apart and no more than 2 weeks apart. Nasal mucosal temperature geometry will be measured after each 12-minute pressure application.

Interventions

Participants will be randomised to receive a pressure of -5cm; 0cm; 5 or 10cmH20 for a period of 12minutes, after a 12 minute acclimation period. (to the room) Participants will return a further 3 times, at which time they will be randomised to receive one of the remaining pressures. Each pressure application will occur not less than two days apart and no more than 2 weeks apart. Nasal mucosal temperature geometry will be measured after each 12-minute pressure application.

Study design

Allocation

Randomised controlled trial

Intervention model

Crossover

Primary purpose

Treatment

Masking

Blinded (masking used)

Eligibility

Sex/Gender

All

Age

18 Years to 55 Years

Healthy volunteers

Inclusion criteria

A clinical history suggestive of normal nose and upper airway, other than during a cold.Willingness of the subject to participate in and complete the study, and the ability to understand the purpose of the trial.

Exclusion criteria

Physical sign or symptoms suggestive of renal, hepatic or cardiovascular disease.Women of childbearing potential who are pregnant, trying to become pregnant or nursing a child.Subjects treated with systemic steroids during the previous 30 days.Subjects treated with topical (inhaled, intranasal or intraocular) steroids, Nasalcrom or Opticrom during the previous 15 days.Subjects treated with oral antihistamine/decongestants during the previous seven days.Subjects treated with topical (intranasal or intraocular) antihistamine/decongestants during the previous 3 days.Subjects treated with immunotherapy.Subjects on chronic anti-asthma medications.Subjects with polyps in the nose or a significantly displaced septum.Subjects who have incurred an upper respiratory tract infection within 14 days of the start of the study.

Outcome results